- Home
- USIO vs MAIA Comparison
USIO vs MAIA Comparison
Compare USIO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USIO
- MAIA
- Stock Information
- Founded
- USIO 1998
- MAIA 2018
- Country
- USIO United States
- MAIA United States
- Employees
- USIO N/A
- MAIA N/A
- Industry
- USIO Investment Bankers/Brokers/Service
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- USIO Finance
- MAIA Health Care
- Exchange
- USIO Nasdaq
- MAIA Nasdaq
- Market Cap
- USIO 41.5M
- MAIA 47.7M
- IPO Year
- USIO N/A
- MAIA 2022
- Fundamental
- Price
- USIO $1.42
- MAIA $1.60
- Analyst Decision
- USIO Strong Buy
- MAIA
- Analyst Count
- USIO 2
- MAIA 0
- Target Price
- USIO $5.00
- MAIA N/A
- AVG Volume (30 Days)
- USIO 118.4K
- MAIA 145.1K
- Earning Date
- USIO 03-26-2025
- MAIA 03-24-2025
- Dividend Yield
- USIO N/A
- MAIA N/A
- EPS Growth
- USIO N/A
- MAIA N/A
- EPS
- USIO 0.13
- MAIA N/A
- Revenue
- USIO $81,027,258.00
- MAIA N/A
- Revenue This Year
- USIO $2.58
- MAIA N/A
- Revenue Next Year
- USIO $13.40
- MAIA N/A
- P/E Ratio
- USIO $10.71
- MAIA N/A
- Revenue Growth
- USIO N/A
- MAIA N/A
- 52 Week Low
- USIO $1.24
- MAIA $1.29
- 52 Week High
- USIO $2.92
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- USIO 36.10
- MAIA 37.84
- Support Level
- USIO $1.37
- MAIA $1.46
- Resistance Level
- USIO $1.57
- MAIA $1.79
- Average True Range (ATR)
- USIO 0.10
- MAIA 0.14
- MACD
- USIO -0.02
- MAIA -0.02
- Stochastic Oscillator
- USIO 13.95
- MAIA 22.22
About USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for the Output Solutions operations.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.